Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).
Voyager Therapeutics (VYGR) was founded in 2013 and is still an early stage developer of gene therapies targeting neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial (and other partnered trials) for the treatment of Parkinson's disease. Other assets are preclinical....
Avisol Capital Partners on Seeking Alpha | January 18, 2021
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 308,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $110.22, for a total value of $33,975,315.00. Following the completion of the sale, the chief executive officer now owns 584,520 shares in […]
California-based biopharmaceutical company Neurocrine Biosciences reported worse-than-expected earnings in the fourth quarter as sales disappointed on anticipated inventory destocking; however, the shares rose over 7% on Friday.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of INGREZZA® (valbenazine) for 2020, and key commercial and clinical development milestones for 2021. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference to be held virtually on Monday, January 11 at 2:00 p.m. Eastern Time, followed by a Question and Answer session at approximately 2:20 p.m. Eastern Time.